scholarly journals Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision

Cancers ◽  
2018 ◽  
Vol 10 (2) ◽  
pp. 57 ◽  
Author(s):  
Kelsey Lewis ◽  
Karen Lu ◽  
Amber Klimczak ◽  
Samuel Mok
Keyword(s):  
Ovarian Cancer ◽  
At Risk ◽  
Brca Mutation ◽  
Mutation Carriers ◽  
Brca Mutation Carriers

scholarly journals Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer

2017 ◽  
Vol 24 (11) ◽  
pp. 3116-3123 ◽  
Author(s):  
Charlotte Gamble ◽  
Laura J. Havrilesky ◽  
Evan R. Myers ◽  
Junzo P. Chino ◽  
Scott Hollenbeck ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cost Effectiveness ◽  
Brca Mutation ◽  
Mutation Carriers ◽  
Brca Mutation Carriers ◽  
History Of ◽  
Risk Reducing

scholarly journals Factors Impacting on Decision-Making towards Prophylactic Surgeries in BRCA Mutation Carriers and Women with Familial Predisposition

Breast Care ◽  
2019 ◽  
Vol 15 (3) ◽  
pp. 253-259
Author(s):  
Robin Segerer ◽  
Clara Peschel ◽  
Ulrike Kämmerer ◽  
Sebastian Häussler ◽  
Achim Wöckel ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Decision Making ◽  
Brca Mutation ◽  
Prophylactic Surgery ◽  
Sexual Life ◽  
Familial Predisposition ◽  
Emotional Factors ◽  
Mutation Carriers ◽  
Brca Mutation Carriers ◽  
Psychological Predictor

Background/Objectives: BRCA mutation carriers and women at high risk of breast/ovarian cancer are faced with the intricate question to opt for prophylactic surgeries and/or a periodic screening. The aim of this study was therefore to identify objective and emotional factors that have an impact on the decision-making process. Methods: Ninety-five women with BRCA mutations or women at increased breast/ovarian cancer lifetime risk were counseled at our outpatient department and either opted for prophylactic surgery or periodic screening. To identify the psychological factors that could have influenced the decision-making, a standardized questionnaire was applied. Additionally, clinical data were collected and were reviewed by a personal talk. Results: Seventy-one of the patients opted for an increased surveillance only, 21 for prophylactic surgeries. Positive predictors for prophylactic surgeries were sociodemographic characteristics such as parity and objective variables such as verified mutation status. Hierarchical regression analysis revealed that the need for safety in health issues has been the only significant psychological predictor of surgery beyond the objective factors. Fear of surgical procedures, menopausal symptoms after surgery, loss of attractiveness, or fear of interferences with sexual life did not significantly affect decision-making. Conclusion: Decision-making towards prophylactic surgeries is influenced by objective but also emotional factors. Knowing that fear and anxiety also have an important impact on decision-making, distinct counselling about the procedures, the subsequent risk reduction as well as the psychological effects of prophylactic surgeries are essential.

Breast Cancer Following Ovarian Cancer in BRCA Mutation Carriers

2020 ◽  
Vol 156 (3) ◽  
pp. e14-e15
Author(s):  
A.I. Nañez ◽  
S. Langer ◽  
C. Garcia ◽  
C.B. Powell
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Brca Mutation ◽  
Mutation Carriers ◽  
Brca Mutation Carriers

Comparison of risk-reducing surgery in women with BRCA and non-BRCA ovarian cancer susceptibility genes.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 1547-1547
Author(s):  
Zachary Phillip Schwartz ◽  
Mae Zakhour ◽  
Andrew John Li ◽  
Christine S. Walsh ◽  
Bj Rimel ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Susceptibility ◽  
Brca Mutation ◽  
Susceptibility Genes ◽  
Brca Mutations ◽  
Cancer Susceptibility Genes ◽  
Mutation Carriers ◽  
Brca Mutation Carriers ◽  
History Of ◽  
Risk Reducing

1547 Background: Risk reducing gynecologic surgery (RRSO) is standard of care for women with BRCA mutations. The optimal management for women with non-BRCA ovarian cancer susceptibility mutations remains unclear. We sought to characterize the practice patterns for these women at our two institutions. Methods: Women with germline ovarian cancer susceptibility genes who had a RRSO were identified from 1/2000-1/2019 in an IRB approved study. All patients were asymptomatic with no suspicion for malignancy at time of RRSO. Clinico-pathologic characteristics were extracted from the medical records. Continuous variables were analyzed with Kruskal-Wallis and categorical variables analyzed with chi square and t-tests. Results: 152 BRCA1, 95 BRCA2, and 63 Non-BRCA mutation carriers were identified—50 Lynch (22 MLH1, 13 MSH2, 13 MSH6, 2 PMS2) and 13 Other (6 BRIP1, 2 RAD51C, 5 RAD51D). There was no difference between age at testing, age at RRSO, and interval between testing and RRSO between groups. Genetic counseling was higher in Non-BRCA patients. Family history of ovarian cancer was more common in women with BRCA1 and Other germline mutations compared to BRCA2 and Lynch. Family and personal history of breast cancer was high in all groups except Lynch carriers. Prophylactic mastectomy was seen mostly in BRCA mutation carriers. Concomitant hysterectomy was performed in the majority of women (BRCA1 59%, BRCA2 57%, and Other 62%), with the highest frequency in Lynch carriers (86%, p<.01). Occult cancer was only seen in BRCA mutation carriers: BRCA1 (7%), BRCA2 (2%), Lynch (0%), Other (0%). Conclusions: In this cohort, women with Non-BRCA mutations are managed similarly to women with BRCA mutations. We observed no occult cancers in Non-BRCA patients. The optimal role of surgery as a risk reducing strategy in this group requires further study. [Table: see text]

Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel

2003 ◽  
Vol 89 (3) ◽  
pp. 494-498 ◽  
Author(s):  
G Hirsh-Yechezkel ◽  
A Chetrit ◽  
F Lubin ◽  
E Friedman ◽  
T Peretz ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Brca Mutation ◽  
Mutation Carriers ◽  
Brca Mutation Carriers

scholarly journals The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program

Menopause ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Giovanni Grandi ◽  
Federica Fiocchi ◽  
Laura Cortesi ◽  
Angela Toss ◽  
Fausto Boselli ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Brca Mutation ◽  
Mutation Carriers ◽  
Brca Mutation Carriers

Breast cancer surveillance following ovarian cancer in BRCA mutation carriers

2020 ◽  
Vol 156 (3) ◽  
pp. e14
Author(s):  
I. Cass ◽  
C. John ◽  
J. Gillen ◽  
K.M. Moore ◽  
C. Walsh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Brca Mutation ◽  
Cancer Surveillance ◽  
Mutation Carriers ◽  
Brca Mutation Carriers

Pathologic findings at risk-reducing salpingo-oophorectomy among women at increased ovarian cancer risk: Results from GOG-199.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1519-1519 ◽  
Author(s):  
Phuong L. Mai ◽  
Mark E Sherman ◽  
Marion Piedmonte ◽  
Olga B. Ioffe ◽  
Brigitte M. Ronnett ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Family History ◽  
Brca Mutation ◽  
Brca2 Mutation ◽  
Ovarian Cancer Risk ◽  
Strong Family History ◽  
Mutation Carriers ◽  
Pelvic Cancer ◽  
Brca Mutation Carriers ◽  
Risk Reducing

1519 Background: Although risk-reducing salpingo-oophorectomy (RRSO) is a standard management option for women with BRCA1/2 mutations, the lack of large, prospective cohort studies makes estimating the prevalence of cancer at RRSO problematic. Methods: GOG-199 is a large, non-randomized multi-center trial which enrolled women at high-risk (due to BRCA mutations or strong family history) of ovarian cancer, comparing surgery at enrollment with serial transvaginal ultrasound and CA-125 screening. RRSO specimens were processed according to a standardized tissue processing protocol including 2-3mm sectioning of both ovaries and tubes. Results: 2,605 participants were accrued to GOG-199. Of the 1 030 enrolled in the baseline RRSO cohort, 28 were ineligible and 36 declined surgery after enrollment, resulting in 966 baseline RRSO. Pathology review demonstrated 4 tubal intraepithelial carcinoma and 20 serous pelvic cancers, of which 12 were identified only microscopically. Among the 20 serous cancers, the predominant or exclusive site of involvement was ovary in 10, fallopian tube in 5, and peritoneum in 5 cases. In addition, 6 endometrial cancers (among the 515 undergoing concomitant hysterectomy) and 3 adenocarcinomas suggestive of metastasis were identified. The serous pelvic cancer prevalence was: entire cohort=2.1% (20/966), all BRCA mutation carriers=3.2 (18/558), BRCA1 mutation carriers=3.7% (12/325), BRCA2 mutation carriers=2.6% (6/231), and mutation-negative=0.5% (2/402). Compared to those without cancer, women with serous pelvic cancer were older at surgery (p< .001), and more often menopausal (vs pre-menopausal, p= .002), nulliparous (vs parous, p=.04) and never users of tamoxifen (vs ever users, p= .04). Serous pelvic cancers were more frequent in BRCA mutation carriers (vs no mutation, p= .004), and among carriers, more common in those with BRCA1 mutations (vs BRCA2 mutation, p= .02). Conclusions: The prevalence of serous pelvic cancers in this cohort was 3.2% among carriers vs 0.5% among the mutation-negative but with a strong family history. Our data will be useful when counseling women at increased ovarian cancer risk who are contemplating risk-reducing surgery.

Obesity is associated with poor clinical outcome in BRCA mutation carriers with epithelial ovarian cancer

2020 ◽  
Vol 159 (2) ◽  
pp. e27
Author(s):  
Catherine John ◽  
Ilana Cass ◽  
Christine Walsh ◽  
Bobbie J. Rimel ◽  
Kristin N. Taylor ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Outcome ◽  
Epithelial Ovarian Cancer ◽  
Brca Mutation ◽  
Poor Clinical Outcome ◽  
Mutation Carriers ◽  
Brca Mutation Carriers
Sign in / Sign up

Export Citation Format

Share Document